Published in BMJ Open on July 01, 2015
Advancing methods for US transgender health research. Curr Opin Endocrinol Diabetes Obes (2016) 0.82
The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med (2001) 76.04
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med (2007) 9.05
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
The epidemiology of venous thromboembolism. Circulation (2003) 6.97
Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol (2003) 6.45
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med (2002) 6.10
Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet (1998) 6.04
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
Treatment of venous thromboembolism. JAMA (2014) 2.63
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol (2013) 1.92
miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ (2011) 1.77
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Mini-SPIN: A brief screening assessment for generalized social anxiety disorder. Depress Anxiety (2001) 1.63
Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl) (2011) 1.54
Proteomics of microparticles after deep venous thrombosis. Thromb Res (2010) 1.50
Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. J Vasc Surg (2014) 1.47
Inflammation, innate immunity and blood coagulation. Hamostaseologie (2010) 1.39
Personality and coronary heart disease: the type-D scale-16 (DS16). Ann Behav Med (1998) 1.23
Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost (2011) 1.18
Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis. QJM (2005) 1.17
[The Gutenberg Health Study]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2012) 1.15
Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging (2010) 1.13
C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol (2010) 1.12
C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost (2009) 1.11
Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci (2013) 1.10
Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost (2011) 1.09
Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood (2014) 1.06
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost (2013) 1.05
Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. Clin Chem (2011) 1.04
[Evaluation of the German Type D Scale (DS14) and prevalence of the Type D personality pattern in cardiological and psychosomatic patients and healthy subjects]. Psychother Psychosom Med Psychol (2004) 1.04
Pro-inflammatory role of microrna-200 in vascular smooth muscle cells from diabetic mice. Arterioscler Thromb Vasc Biol (2012) 1.02
Distribution and dose response of laboratory markers to alcohol consumption in a general population: results of the study of health in Pomerania (SHIP). J Stud Alcohol (2003) 0.97
Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. J Thromb Haemost (2009) 0.96
Implementing NICE guidelines on risk assessment for venous thromboembolism: failure, success and controversy. Int J Health Care Qual Assur (2012) 0.95
C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol (2002) 0.95
Biomarkers of deep venous thrombosis. J Thromb Thrombolysis (2012) 0.94
Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost (2014) 0.94
Lessons from genome-wide association studies in venous thrombosis. J Thromb Haemost (2011) 0.89
Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost (2014) 0.87
The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes (2012) 0.87
The up-regulation of endothelin-1 and down-regulation of miRNA-125a-5p, -155, and -199a/b-3p in human atherosclerotic coronary artery. Cardiovasc Pathol (2014) 0.87
Systematic review: diagnostic accuracy of clinical decision rules for venous thromboembolism in elderly. Ageing Res Rev (2010) 0.86
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86
The diagnosis and treatment of venous thromboembolism. Hematology Am Soc Hematol Educ Program (2013) 0.85
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther (2014) 0.85
Management of venous thrombo-embolism: an update. Eur Heart J (2014) 0.84
Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur J Haematol (2012) 0.83
Familial transmission of venous thromboembolism: a cohort study of 80 214 Swedish adoptees linked to their biological and adoptive parents. Circ Cardiovasc Genet (2014) 0.83
Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med (2013) 0.82
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol (2014) 0.82
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis. J Thromb Haemost (2012) 0.81
Performance of five D-dimer assays for the exclusion of symptomatic distal leg vein thrombosis. Thromb Haemost (2012) 0.81
[Screening for depersonalization-derealization with two items of the cambridge depersonalization scale]. Psychother Psychosom Med Psychol (2009) 0.80
Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis. J Vasc Surg Venous Lymphat Disord (2013) 0.80
Diagnosis of recurrent deep vein thrombosis. Hamostaseologie (2013) 0.80
Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulm Circ (2013) 0.78
Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol (2013) 0.78
Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis. Thromb Res (2014) 0.78
Evaluation of oral anticoagulation therapy: rationale and design of the thrombEVAL study programme. Eur J Prev Cardiol (2014) 0.77
Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome. J Thromb Haemost (2015) 0.76
Comprehensive study on laboratory biomarkers for prediction and diagnosis of deep venous thrombosis. Blood Coagul Fibrinolysis (2015) 0.76
Biomarkers for arterial and venous thrombotic disorders. Hamostaseologie (2014) 0.76
Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort. Eur Heart J (2016) 0.78
The impact of pseudophakia on vision-related quality of life in the general population - The Gutenberg Health Study. Aging (Albany NY) (2017) 0.77
New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics. Hum Mol Genet (2017) 0.76
Echicetin coated polystyrene beads: a novel tool to investigate GPIb-specific platelet activation and aggregation. PLoS One (2014) 0.75
Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis (2016) 0.75
Mechanisms of Cellular Activation in the Antiphospholipid Syndrome. Semin Thromb Hemost (2017) 0.75
Refined atrial fibrillation screening and cost-effectiveness in the German population. Heart (2021) 0.75
Refractive, corneal, and ocular residual astigmatism: distribution in a German population and age dependency-the Gutenberg Health Study. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Refractive, corneal and ocular residual astigmatism: distribution in a German population and age-dependency - the Gutenberg health study. Graefes Arch Clin Exp Ophthalmol (2017) 0.75